MetLife Investment Advisors LLC decreased its position in Illumina, Inc. (NASDAQ:ILMN) by 1.2% during the third quarter, HoldingsChannel.com reports. The firm owned 42,763 shares of the life sciences company’s stock after selling 511 shares during the quarter. MetLife Investment Advisors LLC’s holdings in Illumina were worth $15,697,000 as of its most recent filing with the Securities & Exchange Commission.
Other large investors have also recently added to or reduced their stakes in the company. Highstreet Asset Management Inc. bought a new position in shares of Illumina in the third quarter valued at approximately $112,000. Ancora Advisors LLC bought a new position in shares of Illumina in the third quarter valued at approximately $145,000. Sun Life Financial INC raised its position in shares of Illumina by 152.5% in the second quarter. Sun Life Financial INC now owns 399 shares of the life sciences company’s stock valued at $111,000 after purchasing an additional 241 shares during the period. SRS Capital Advisors Inc. bought a new position in shares of Illumina in the third quarter valued at approximately $157,000. Finally, MUFG Americas Holdings Corp bought a new position in shares of Illumina in the third quarter valued at approximately $183,000. 88.91% of the stock is currently owned by institutional investors.
In other Illumina news, SVP Mostafa Ronaghi sold 10,000 shares of Illumina stock in a transaction on Wednesday, October 10th. The shares were sold at an average price of $311.84, for a total transaction of $3,118,400.00. Following the sale, the senior vice president now owns 80,805 shares in the company, valued at $25,198,231.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Robert S. Epstein sold 1,346 shares of Illumina stock in a transaction on Monday, October 1st. The stock was sold at an average price of $369.15, for a total transaction of $496,875.90. The disclosure for this sale can be found here. Insiders have sold 61,726 shares of company stock worth $20,077,106 in the last quarter. Corporate insiders own 0.54% of the company’s stock.
Illumina (NASDAQ:ILMN) last posted its quarterly earnings results on Tuesday, October 23rd. The life sciences company reported $1.52 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.26 by $0.26. Illumina had a net margin of 21.09% and a return on equity of 27.10%. The firm had revenue of $853.00 million for the quarter, compared to the consensus estimate of $825.65 million. During the same quarter in the previous year, the company earned $1.11 earnings per share. The business’s revenue was up 19.5% compared to the same quarter last year. Analysts predict that Illumina, Inc. will post 5.75 EPS for the current year.
ILMN has been the topic of a number of research reports. UBS Group initiated coverage on shares of Illumina in a research report on Tuesday, October 9th. They set a “neutral” rating and a $340.00 target price on the stock. Zacks Investment Research lowered shares of Illumina from a “buy” rating to a “hold” rating in a research report on Wednesday, October 24th. BidaskClub lowered shares of Illumina from a “buy” rating to a “hold” rating in a research report on Tuesday, October 16th. Deutsche Bank boosted their target price on shares of Illumina to $350.00 and gave the stock a “buy” rating in a research report on Friday, October 12th. Finally, Piper Jaffray Companies boosted their target price on shares of Illumina to $380.00 and gave the stock an “overweight” rating in a research report on Tuesday, October 2nd. Six investment analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $330.94.
WARNING: “Illumina, Inc. (ILMN) Stake Lowered by MetLife Investment Advisors LLC” was reported by BBNS and is the property of of BBNS. If you are accessing this piece on another website, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece can be read at https://baseballnewssource.com/2018/12/16/illumina-inc-ilmn-stake-lowered-by-metlife-investment-advisors-llc/3085127.html.
Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing by synthesis technology that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as allow the detection of known genetic markers on a single array.
Recommended Story: What is a Derivative?
Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.